Entrada Therapeutics Inc
NASDAQ:TRDA 1:08:38 PM EDT
| Market Cap (Intraday) | 423.34M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $12.63 |
| 50-Day MA | $13.10 |
| 200-Day MA | $14.66 |
Entrada Therapeutics Inc Stock, NASDAQ:TRDA
One Design Center Place, Boston, Massachusetts 02210
United States of America
Phone: +1.857.520.9158
Number of Employees: 159
Description
Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.